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Background: Impulsive and compulsive behaviors (ICBs) are a heterogeneous group of
conditions that may be caused by long-term dopaminergic replacement therapy (DRT) of
Parkinson’s disease (PD).The spectrum of ICBs includes dopamine dysregulation syndrome
(DDS), punding, and impulse control disorders (ICDs).
Contents: We made a detailed review regarding the epidemiology, pathology, clinical
characteristics, risk factors, diagnosis as well as treatment of ICBs.
Results:The prevalence of ICBs in PD patients is approximately 3–4% for DDS, 0.34–4.2%
for punding, and 6–14% for ICDs, with higher prevalence in Western populations than in
Asian.Those who take high dose of levodopa are more prone to have DDS, whereas, ICDs
are markedly associated with dopamine agonists. Different subtypes of ICBs share many
risk factors such as male gender, higher levodopa equivalent daily dose, younger age at
PD onset, history of alcoholism, impulsive, or novelty-seeking personality. The Question-
naire for Impulsive–Compulsive Disorder in Parkinson’s Disease-Rating Scale seems to be
a rather efficacious instrument to obtain relevant information from patients and caregivers.
Treatment of ICBs is still a great challenge for clinicians. Readjustment of DRT remains the
primary method. Atypical antipsychotics, antidepressants, amantadine, and psychosocial
interventions are also prescribed in controlling episodes of psychosis caused by compul-
sive DRT, but attention should be drawn to balance ICBs symptoms and motor disorders.
Moreover, deep brain stimulation of the subthalamic nucleus might be a potential method
in controlling ICBs.
Conclusion:The exact pathophysiological mechanisms of ICBs in PD remains poorly under-
stood. Further researches are needed not only to study the pathogenesis, prevalence,
features, and risk factors of ICBs, but to find efficacious therapy for patients with these
devastating consequences.
Keywords: Parkinson disease, impulsive control disorders, dopamine dysregulation syndrome, review,
dopaminergic replacement therapy
INTRODUCTION
Idiopathic Parkinson’s disease (PD) is a chronic progressive neu-
rodegenerative disorder resulted from dopaminergic cell loss in
the substantia nigra (Evans et al., 2005). Impulsive and com-
pulsive behaviors (ICBs), a heterogeneous group of peculiarly
additional actions, have emerged as an iatrogenic complication
due to dopamine replacement therapy (DRT) in PD patients.
ICBs consist of dopamine dysregulation syndrome (DDS), pund-
ing, and impulse control disorders (ICDs) (Voon et al., 2006;
Mamikonyan et al., 2008; Evans et al., 2009; Wu et al., 2009; Wein-
traub et al., 2010). DDS occurs mostly due to compulsive overuse
Abbreviations: DAs, dopamine agonists; DDS, dopamine dysregulation syndrome;
DRT, dopamine replacement therapy; ICBs, impulsive and compulsive behaviors;
ICDs, impulse control disorders; ISS, impulsivity and sensation seeking; LEDD,
levodopa equivalent daily dose; LF-rTMS, low-frequency repetitive transcranial
magnetic stimulation; NMDA, N -methyl-d-aspartic acid; PD, Parkinson’s disease;
PG, pathological gambling; QUIP, questionnaire for impulsive–compulsive disor-
ders in Parkinson’s disease; SSRIs, selective serotonin reuptake inhibitors; STN-DBS,
deep brain stimulation of the subthalamic nucleus.
of dopaminergic treatment, resulting in secondary cognitive and
behavioral disturbances (Evans et al.,2009;Wu et al.,2009).“Pund-
ing” is a stereotypical motor behavior characterized by an intense
fascination with repetitive, excessive and non-goal oriented han-
dling, and examining of objects (Evans et al., 2004). The main
subtypes of reported ICDs include pathological gambling (PG),
hypersexuality, compulsive eating, and shopping, of those the first
two are more common in male PD patients whereas the last two
tend to be more frequently reported in females (Voon et al., 2006;
Weintraub et al., 2010). ICDs are considered separately given their
proven association with dopamine agonists (DAs) in multiple case
control studies (Avanzi et al., 2006; Grosset et al., 2006; Voon et al.,
2006; Weintraub et al., 2006), as compared with DDS, which seems
to be more closely associated with levodopa (Evans et al., 2005),
and punding, whose association with levodopa or DAs is not yet
clear (Evans et al., 2004; Lawrence et al., 2007; Miyasaki et al.,
2007). ICBs are particularly requisite to recognize because not only
these symptoms are under-recognized (Avila et al., 2011a), but
they can raise considerable burden to patients, their families, and
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society. More than a quarter of PD patients with ICBs have two or
more behavioral addictions (Ondo and Lai, 2008; Weintraub et al.,
2010). In this review, we aim to provide readers with a compressive
understanding of the epidemiology, clinical features, pathophysi-
ology, risk factors, and treatment of ICBs, allowing greater insight
into potential dominance of ICBs in PD patients.
DOPAMINE DYSREGULATION SYNDROME
PREVALENCE
Dopamine dysregulation syndrome, also called hedonistic home-
ostatic dysregulation, is a disturbance that may complicate long-
term DRT in PD patients (Evans and Lees, 2004; O’Sullivan et al.,
2009). Prevalence of DDS in general population of PD patients
is underestimated to be 3–4% (Evans and Lees, 2004; O’Sullivan
et al., 2009) as patients are reluctant to discuss their embarrass-
ing behaviors. The available data all come from specialist referral
centers with inherent selection biases more or less. In a UK-based
study, 15 of 364 PD patients (4.1%) were diagnosed with DDS.
Similar results were reported by an Italian movement disorders
clinic, with 7 of 202 PD patients (3.4%) exhibiting DDS.
CHARACTERISTIC AND PATHOLOGY
Dopamine dysregulation syndrome is characterized by a bizarre
phenomenon of an ineffectiveness of medications during “off”
periods, and PD patients typically excuse this for maintaining
not self-administering doses but an addiction of dopaminergic
drugs in excess of those required to control their motor symp-
toms (Lawrence et al., 2003; Evans et al., 2005). After a period
of treatment with high Levodopa equivalent daily dose (LEDD),
drug-induced dyskinesias emerge together with socially harmful
behaviors (Giovannoni et al., 2000; Merims et al., 2000). Avanzi
et al. (2008) reported two male PD patients developing compul-
sive risk-seeking driving behavior as a result of self-administering
high doses of levodopa. Occurrence of DDS was speculated to be
due to short duration of levodopa action (Evans and Lees, 2004;
Gallagher et al., 2007; O’Sullivan et al., 2009). Recently, DDS was
also reported to be related to DA withdrawal syndrome (Limotai
et al., 2012). Levodopa is still considered as the most potent trigger
of DDS, but subcutaneous apomorphine and oral DAs may also
be responsible (O’Sullivan et al., 2009). Additionally, the develop-
ment of physiological tolerance to levodopa is mediated by central
pharmacokinetic and pharmacodynamic changes related to pro-
gressive dopaminergic denervation. In PD patients with DDS,
however, the psychological effects of “wearing-off” often precede
any discernable physical changes. Evidence of maladaptations and
sensitization occurring in DDS was noted as enhanced levodopa-
induced ventral striatal dopamine release when compared with
PD patients who do not compulsively taking dopaminergic drugs
(Evans et al., 2006).
RISK FACTORS AND POTENTIAL MECHANISMS FOR DDS
DEVELOPMENT
Personality traits related to impulsivity and sensation seeking (ISS)
are associated with drug dependence, drug craving, and vulnera-
bility to relapse. They also play a prominent role in the devel-
opment of DDS (O’Sullivan et al., 2009). ISS traits, which include
novelty-seeking and sensation seeking, are thought to be mediated
through mesolimbic dopaminergic systems (Leyton et al., 2002).
PD patients with DDS tend to have greater experimental drug use,
higher score on ISS ratings, higher alcohol intake and younger
PD onset than healthy controls or other PD patients without DDS
(Evans et al., 2005; Gallagher et al., 2007;Voon et al., 2007). Besides,
disruption of the reciprocal loops between the striatum and struc-
tures in the prefrontal cortex following dopamine depletion may
predispose to DDS (O’Sullivan et al., 2009). Several studies seeking
for candidate genes that may affect the dopamine “D2-like” recep-
tor family and may be associated with impulsive personality traits
got conflicting results (Strobel et al., 2003; Tsai et al., 2004). All
in all, age at onset and novelty-seeking personality traits are con-
sidered to be the two strongest predictors of DDS in PD patients
(Evans et al., 2005; Ondo and Lai, 2008).
TREATMENT FOR DDS
Detailed, cautious, and specific enquiries to family members are
essential. As outlined in most reports, once PD patients develop
DDS, their long-term management becomes difficult (Evans et al.,
2005; O’Sullivan et al., 2009; Katzenschlager, 2011). Discontinua-
tion or reduction of dopaminergic drug does, levodopa particu-
larly, should be the first adjustment, which may, however, induce
severe motor disorder, depression, or anxiety. Once these condi-
tions occurred, antidepressants should be considered regardless of
data available are limited currently about the preferred subtypes
of antidepressants in treating DDS. Reports based on cocaine-
addicted individuals demonstrated that tricyclic antidepressants
might be related with an increased risk of relapse. In addition
to pharmaceutical therapies discussed above, deep brain stimu-
lation of the subthalamic nucleus (STN-DBS) is an established
therapy for advanced PD patients with the potential not only to
allow significant reductions in drug dose but may improve “off”-
medication motor symptoms (Weaver et al., 2009). However, the
relationship between DDS and STN-DBS remains controversial
(Schupbach et al., 2005; Witjas et al., 2005; Bandini et al., 2007;
Lim et al., 2009; Eusebio et al., 2013). In 17 PD patients with
DDS received bilateral STN-DBS, 12 were resolved or dramati-
cally improved post-operatively (Krack et al., 2003; Funkiewiez
et al., 2004; Witjas et al., 2005; Bandini et al., 2007; Knobel et al.,
2008), but the remaining 5 patients failed to improve or even
worsened (Houeto et al., 2002; Schupbach et al., 2005). Many
postoperative PD patients overused dopaminergic drugs to avoid
anxiety, dysphoria, and other non-motor symptoms (Evans et al.,
2010). The combined effect of DRT and DBS on the limbic terri-
tory of the subthalamic nucleus could have precipitated DDS in
these patients by inducing hyper-stimulation of the mesolimbic
dopamine system (De la Casa-Fages and Grandas, 2012). Con-
tinuous jejunal levodopa infusion might have positive effects on
DDS, ICDs, and punding as well as motor complications in PD
patients (Nyholm et al., 2003, 2005; Odin et al., 2008; Devos, 2009;
Catalan et al., 2013). However, the new therapy may not be useful
in every instance because it also trigger behavioral abnormalities
in sensitive PD patients (Cannas et al., 2013). Due to the putative
efficacy of controlling ICBs with levodopa has only been described
with small subjects groups (Gerschlager and Bloem, 2009; Vallde-
oriola and Camara, 2010; Catalan et al., 2013), further randomized
controlled trials are urgently needed.
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PUNDING
PREVALENCE
Prevalence of punding varies greatly in different studies because
of disparities in study populations, assessment methods (ques-
tionnaire or direct interview) as well as diagnostic criteria. It is
estimated to be between 0.34 and 14% in PD patients taking
high doses of levodopa (> 800 mg/day). However, due to both the
absence of related knowledge to punding among clinicians and
reluctance of patients to debate their behaviors spontaneously, a
widespread under-recognition of punding might have existed up
to present (O’Sullivan et al., 2007; Fasano et al., 2008, 2010; Spencer
et al., 2011).
PATHOLOGY
Theories on the possible pathophysiology of punding in PD
patients are still highly speculative. Previous studies found lesions
to the basal ganglia might induce stereotyped behaviors, which
resembled punding. Studies supported a causative role of abnor-
mal dopaminergic transmission in the pathogenesis of punding
(Spencer et al., 2011). The link between punding and high doses
of DRT has already been established (Black and Friedman, 2006;
Ferrara and Stacy, 2008; Wolters et al., 2008) including levodopa,
DAs, and other alternative medicine (Fernandez and Friedman,
1999; Evans et al., 2004; Miwa et al., 2004; Fasano et al., 2006;
Bonvin et al., 2007; Miyasaki et al., 2007). Additionally, the link
between punding and dopamine D1, D2 agonists was proved to be
closer than D3 and D4 agonists (Fasano and Petrovic, 2010). More-
over, punders were significantly more likely to use dopaminergic
drugs acting on D1 receptor such as apomorphine and cabergo-
line than non-punders (Evans et al., 2004). Suárez et al. (2014)
noted that chronic levodopa therapy alters the synaptic efficacy
in D1 and D2 striatal medium spiny neurons. However, other
researchers failed to find identifiable receptor stimulation profile
(Silveira-Moriyama et al., 2006). Recent studies hypothesized that
levodopa-induced dyskinesias and behavioral disorders observed
in DDS and punding shared common mechanisms (Murer and
Moratalla, 2011) involving alterations of glutamate homeostasis
with combined activation of sensitized dopamine and NMDA
receptors (Kalivas, 2009).
CLINICAL CHARACTERISTICS
“Punding” is a set of aimless, stereotypical motor behaviors char-
acterized by an intense fascination with repetitive manipulat-
ing and examining familiar objects (Black and Friedman, 2006).
Many studies noted punding behaviors often arose from premor-
bid idiosyncratic habits, occupations, and pastimes (Evans et al.,
2004; O’Sullivan et al., 2007). In contrast to other ICBs, pund-
ing is not driven by pleasure, anxiety, or obsessions. Patients
demonstrate more behaviors that appear similar to traits seen
in obsessive–compulsive disorders but more idiosyncratic and
less distressing. However, any interruption or disruption of the
activity often leads to irritation, anxiety, and frustration (Ful-
lana et al., 2009). Punders are aware of the inapposite obtuse
nature of the behaviors but even self-injury resulting from the
stereotypes does not abort them (Evans et al., 2004). A posi-
tive correlation between the severities of punding and dyskinesia
was found (Silveira-Moriyama et al., 2006). Moreover, a 52.8%
higher prevalence of dyskinesia in punders over non-punders
in Japan was reported (Miwa et al., 2004). Recently, repeti-
tive behaviors are considered as an idiosyncratic side effect to
dopaminergic therapy but not a dose- or duration-dependent
phenomenon (Nguyen et al., 2010). Independently predictive fac-
tors of higher Punding Scale scores include higher impulsivity,
poorer disease-related quality of life, younger age of PD onset,
and higher daily medication dosage of DAs (Lawrence et al.,
2007).
TREATMENT
As pathophysiological mechanisms underlying punding have not
been elucidated, it is difficult to develop therapeutic methods.
The most efficacious strategy is proposed to prevent and diag-
nose the appearance of punding earlier. Physicians should be
aware of normal to abnormal symptoms of punding as these
behaviors are frequently undistinguishable and patients can not
realize aberrant behaviors spontaneously with impaired insight.
Specific treatment strategies should be adopted once punding is
diagnosed: (1) the primary method is reduction of dopaminergic
medications (Avila et al., 2011b). Symptoms of punding improved
strikingly after reduction or cease of levodopa or DAs (Fernan-
dez and Friedman, 1999; Kumar, 2005; Miwa and Kondo, 2008).
However, caution is required to get a careful balance between
the control of side effects and deterioration of motor symptoms
(Aquino et al., 2013). Entacapone could be adopted in case of
worsened motor condition (Evans et al., 2004). Selegiline, which
was reported to enhance the levodopa function and generate
amphetamine-like metabolites, should be avoided in PD patients
with punding (Shin, 1997); (2) atypical antipsychotics, such as
quetiapine and clozapine, are another therapy that may improve
punding symptoms, but curative effect is inconsistent (Fasano
et al., 2006, 2011; Bonvin et al., 2007; Miwa and Kondo, 2008;
Hardwick et al., 2013). However, atypical antipsychotics are still
recommended in controlling episodes of psychosis caused by com-
pulsive DRT use and in raising overnight sleep time (Lawrence
et al., 2003); (3) amantadine was recently reported to reduce pund-
ing by blocking N -methyl-d-aspartic acid receptors (Kashihara
and Imamura, 2008; Fasano et al., 2011). However, further evi-
dence to prove the effect is demanded and clinicians should
regard the potential induction or worsening of psychosis due to
the application of amantadine; (4) whether selective serotonin
reuptake inhibitors (SSRIs) is efficacious in punding treatment
has come to no conclusion (Kurlan, 2004; Miwa and Kondo,
2008) though SSRIs are shown to be effective in ICDs; (5) data
regarding the effect of DBS surgery on punding symptoms in PD
patients are limited. Symptoms may worsen, persist, or develop
for the first time after DBS regardless of targeting the subthala-
mic nucleus or the globus pallidus internus (Lim et al., 2009); (6)
though low-frequency repetitive transcranial magnetic stimula-
tion (LF-rTMS) has acquired beneficial effects in treating PD and
levodopa-induced dyskinesia, effects on punding are uncertain.
Recently, Nardone et al. (2013) reported that LF-rTMS produced
therapeutic potential for punding, similar to that reported in PD
patients with levodopa-induced dyskinesias. However, large-scale,
definite studies should still be executed to test the validity of
LF-rTMS.
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IMPULSE CONTROL DISORDERS
PREVALENCE
The frequency of ICDs among PD patients ranges from 6 to 18.4%
in Western studies (Fan et al., 2009; Lee et al., 2010;Weintraub et al.,
2010; Auyeung et al., 2011; Callesen et al., 2013; Poletti et al., 2013).
Weintraub et al. (2010) reported ICDs prevalence of 13.6% in a
cross-sectional study by interviewing 3090 idiopathic PD patients
in the United States and Canada. Valenca et al. (2013) found a
higher ICDs prevalence (18.4%) in Brazil, which might be due to
a higher proportion of DAs usage (89.3%). Recently, two stud-
ies suggested unexpectedly higher prevalence of 34.8 and 25% in
Finnish and French, respectively (Joutsa et al., 2012b; Perez-Lloret
et al., 2012). In contrast with Western countries, studies of preva-
lence and related predisposing factors of ICDs in Asian PD patients
are relatively limited (Fan et al., 2009; Auyeung et al., 2011; Lim
et al., 2011; Chiang et al., 2012; Tanaka et al., 2013) (Table S1
in Supplementary Material). Auyeung et al. (2011) reported that
the prevalence of ICDs was 7% in Chinese PD subjects, which
was higher than the previous reported prevalence of 3.53% (Fan
et al., 2009). Multiple factors might explain the diverse preva-
lence of ICDs such as ethnic differences, environmental, cultural,
and social factors as well as the dosage and type of dopaminergic
medications (Chiang et al., 2012).
PATHOLOGICAL MECHANISM
The exact mechanisms for ICDs development remain unknown.
Reward-seeking behavior is mediated by the amygdala and nucleus
accumbens, both of which receive dopaminergic projections from
the ventral tegmental area (Ambroggi et al., 2008). This may be a
pathological mechanism underlying DRT and ICDs that matters.
Enhanced ventral striatal dopamine release due to hypersensiti-
zation of the ventral striatal circuitry may be another explana-
tion (Evans et al., 2006). Complex interactions between DAs and
dopamine receptor subtypes may lead to the development of ICDs
in PD patients (Pontone et al., 2006). DAs, such as pramipexole
and ropinirole, have remarkably specific binding affinities with D3
receptor (Gerlach et al., 2003), which are at least 100-fold greater
than with D2 or D1 receptor. As a potential drug target, therefore,
D3 receptor known to be localized to the mesolimbic system and
involved with reward and motivated behaviors has aroused great
concerns (Weintraub, 2008). This might be a momentous expla-
nation why it was not levodopa or carbidopa but DAs that led to
ICDs more frequently. Consequently, D3 antagonists might pos-
sess therapeutic utility in the resolution of pathological behaviors
with elimination or reduction of the D3-preferring agonist (Dodd
et al., 2005; Klos et al., 2005; Singh et al., 2007; Bostwick et al.,
2009; Hassan et al., 2011). Experiments have been undertaken to
test the efficacy of selective D3 receptor antagonists in rat models
(Xi et al., 2004; Pak et al., 2006). Except for its larvaceous benefit in
animal models (Peng et al., 2009; Khaled et al., 2010; Higley et al.,
2011), D3 antagonists have also been administered to humans in
single doses for imaging researches (Graff-Guerrero et al., 2010;
Searle et al., 2010). CC genotype of the 2B subunit of the gluta-
mate NMDA receptor might be more frequent in PD patients with
ICDs than non-affected ones (Lee et al., 2009). Recently, a genetic
variant affecting serotonin 2A receptor pathway was found to be
associated with ICDs in PD patients receiving DRT, mainly under
low-dopaminergic-dose conditions (Lee et al., 2012). Moreover,
in comparison with PD patients without ICDs, those who have
ICDs present severer cognitive impairments, particularly executive
functions (Santangelo et al., 2009; Voon et al., 2010; Barone et al.,
2011). Specific difficulties in inhibitory control during cognitive
or motor performances have also been involved in the etiology of
ICDs development (Seiss and Praamstra, 2004).
CLINICAL MANIFESTATION
Impulse control disorders are a group of disorders characterized
by failure to resist an impulse, drive, or temptation to perform
harmful acts to the person or to others. The primary subtypes
of ICDs include PG, hypersexuality, compulsive eating, and shop-
ping, of which mere PG is included in the DSM-IV-TR. Except
the categories mentioned above, many infrequent behaviors have
been reported (Table S2 in Supplementary Material). In recent
years, increasing evidence and awareness regarding the relation-
ship between ICDs as motor complications and DRT in PD
patients have arisen (Voon and Fox, 2007). The syndrome typically
develops in male patients with early onset, orally or subcuta-
neously administered DRT (Lawrence et al., 2003; Giladi et al.,
2007). Comparing 193 PD patients with 190 age/gender-matched
healthy controls, Giladi et al. (2007) observed that male gender,
younger age at PD motor symptom onset, and longer duration of
treatment with DAs contributed independently and additively to
the risk of developing ICDs. Except for features discussed, psychi-
atric co-morbidities are always companied as another important
factor predisposing to ICDs.
ICDs AND DOPAMINE AGONISTS
Parkinson’s disease patients treated with DAs are more prone
to develop ICDs than those do not use DAs (17.1 vs. 6.9%)
(Weintraub et al., 2010). Dopaminergic augmentation of risk-
taking behaviors may be a potential contributing mechanism for
the emergence of ICDs in PD patients (Claassen et al., 2011).
Weintraub et al. (2010) reported that ICD was present in 17.7%
of PD patients taking both DAs and levodopa, 14.0% taking
DAs, and 7.2% taking levodopa alone. Although the associa-
tion between dopaminergic therapy and ICDs has been revealed,
dose-dependent effect is not yet clear (Weintraub et al., 2010;
Ambermoon et al., 2011; Voon et al., 2011a; Joutsa et al., 2012b).
Cross-sectional studies are less effective in detecting possible dose-
dependent effects because of variations in both the optimal agonist
dose for controlling motor symptoms of PD and the severity of
ICDs. Longitudinal studies, therefore, prone to be more essential.
A few prospective studies investigated the relationship between
ICDs and DAs reduction (Singh et al., 2007; Mamikonyan et al.,
2008; Macphee et al., 2009; Bharmal et al., 2010; Joutsa et al.,
2012a). After following up 290 Finnish PD patients for 15 months,
Joutsa et al. (2012a) reported the effect of DAs on ICDs was dose-
dependent. Acting on D1 receptor as well as aberrant and excessive
expression of D3 receptor in the denervated dorsal striatum (Bor-
det et al., 1997; Bezard et al., 2003), levodopa tends to be related to
ICDs with potential sensitizing or synergistic effects (Weintraub,
2008). Moreover, selegiline, rasagiline (two types of monoamine
oxidase inhibitors type B), and lamotrigine (an anti-epileptic drug
that decreases glutamate release in the synapse) were also reported
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to cause ICDs (Grabowska-Grzyb et al., 2006; Shapiro et al., 2006;
Reyes et al., 2013).
TREATMENT
Management of ICDs in PD patients presents challenges for
clinicians because not only patients cannot wake up to aber-
rant behaviors but also no effective medicines are developed for
ICDs. Most evidence reported on management of ICDs comes
from empirical data with limited clinical trials to identify effica-
cious treatment. Once ICDs are diagnosed, patients should reduce
or discontinue the dopaminergic drugs carefully to prevent the
deterioration of motor symptoms or DA withdrawal symptoms,
including anxiety, dysphoria, fatigue, dysautonomia, sleep distur-
bance, generalized pain, and medication cravings (Rabinak and
Nirenberg, 2010). Discontinuing or significantly decreasing DAs
exposure, even when offset by an augment of levodopa dosage, is
momentous to balance the control of motor disorder and aberrant
behaviors (Dodd et al., 2005; Mamikonyan et al., 2008). Besides,
cognitive-behavioral therapies are receiving empirical support in
non-PD populations and may be encouraged in PD patients (Car-
roll and Onken, 2005; Dowling et al., 2006). Moreover, antipsy-
chotic drugs such as olanzapine or quetiapine coupled with either
DAs or levodopa may be efficacious in ICDs treatment (Grant et al.,
2008). The relationship between ICDs and DBS was reported with
inconsistent results. PG improved or disappeared after bilateral
STN-DBS in nine patients (Molina et al., 2000; Ardouin et al.,
2006). However, in the remaining 18 patients (11 bilateral, 1 uni-
lateral, and 6 not specified), ICDs or punding developed or turned
decompensated post-operatively (8 PG, 7 hypersexuality, 2 pund-
ing, 1 intermittent explosive disorder, and kleptomania) (Romito
et al., 2002; Kleiner-Fisman et al., 2003; Sensi et al., 2004; Machado
et al., 2005; Ardouin et al., 2006; Lu et al., 2006; Morgan et al., 2006;
Smeding et al., 2006, 2007). Selective stimulation of limbic region
of STN and surrounding structures was also reported to trigger
or worsen non-motor side effects (Voon et al., 2005, 2008; Frank
et al., 2007; Mallet et al., 2007; Alberts et al., 2008; Moum et al.,
2012). Therefore, many reports speculated the positive outcomes
after STN-DBS might be related to discontinuation of dopamin-
ergic treatment after surgery (Santangelo et al., 2013). Castrioto
et al. concluded that STN-DBS could not only improve motor
and non-motor behaviors, but induce excessive motor, cognitive,
and emotional behavioral disinhibition. Fine-tuning of stimula-
tion parameters with dopaminergic drugs was necessary to prevent
or improve pathological behaviors (Castrioto et al., 2014).
RISK FACTORS FOR THE DEVELOPMENT OF ICBs
Multiple risk factors contributed to the occurrence of ICBs. The
association between dopaminergic drugs treatment, particularly
DAs in higher dosages, and ICBs has raised much concerns
(Lawrence et al., 2003, 2007; Maia et al., 2003; Evans and Lees,
2004; Klos et al., 2005; Pontone et al., 2006; Giladi et al., 2007;
Voon and Fox, 2007; Voon et al., 2007; Mamikonyan et al., 2008;
Weintraub et al., 2010; Auyeung et al., 2011). Giladi et al. (2007)
demonstrated it was not only the exposure to DAs that was asso-
ciated with the development of addiction-like behaviors but the
behaviors were dose- and time-dependent. Many other poten-
tial risk factors have also drawn much attention. Male gender,
younger age at PD onset, levodopa treatment (especially when
given in combination), higher novelty-seeking personality traits,
and psychosocial factors such as substance abuse and depression
may also predispose patients to developing ICBs (Lawrence et al.,
2003, 2007; Evans and Lees, 2004; Evans et al., 2004, 2005, 2009;
Voon et al., 2006, 2007; Giladi et al., 2007; Wu et al., 2009; Poletti
and Bonuccelli, 2012). Pezzella et al. screened 202 PD patients for
DDS and found a significant correlation between DDS and both
history of mood disorders and previous use of DRT, especially DAs,
either as monotherapy or in combination. Joutsa et al. (2012a)
concluded that ICDs were not only more frequent in men but also
approximate six times more unlikely to be resolved compared to
women after a 15-months follow-up. Sossi et al. (2006) pointed out
that younger sick brain was likely to be more sensitive to DRT, and
dopamine turnover in younger-onset patients undergone a greater
alteration and thus likely led to a striking imbalance between
dopamine synthesis, storage, and release. Moreover, greater impul-
sive choice, faster reaction time, faster decision conflicting reaction
time, and executive dysfunction might also contribute to ICDs
in PD patients (Voon et al., 2010). Lately, Voon et al. (2011b)
proposed that ICDs are associated with multiple psychiatric and
cognitive impairments such as affective and anxiety symptoms,
elevated obsessionality, novelty-seeking, and impulsivity. The rela-
tion between PG and depressed mood were also observed (Potenza
et al., 2005; Grant and Potenza, 2006; Romer Thomsen et al., 2009).
Major depression in middle-aged men appeared to be frequently
comorbid with PG, with over-lapping genetic factors contribut-
ing substantially to the co-occurrence (Potenza et al., 2005; Romer
Thomsen et al., 2009). The exact effect of STN-DBS on addic-
tive behaviors in PD patients remains to be further investigated.
The postoperative motor improvement resulting from STN-DBS
showed the potential to allow significant reductions in drug dose
(Schupbach et al., 2005; Witjas et al., 2005; Bandini et al., 2007;
Lim et al., 2009). However, others found no obvious improvement
or even worsened symptoms after surgery (De la Casa-Fages and
Grandas, 2012).
ASSESSMENT OF IMPULSIVE–COMPULSIVE BEHAVIORS IN
PARKINSON’S DISEASE
Assessment instruments for ICBs and related disorders in PD
patients are limited. Diagnostic criteria are defined in the DSM-
IV-TR. Though consisted of many questions about compulsive
gambling, buying, and sexual behavior, the Minnesota Impul-
sive Disorders Interview does not match the style of DSM-IV-TR
and assesses inadequate contents of ICDs. Other disorder-specific
screening instruments used in ICBs including the South Oaks
Gambling Screen, the Buying Questionnaire, and the punding
questionnaire, are also limited with no existing single instrument
fulfilling the criteria of being comprehensive, self-rated, and val-
idated for use. Though the DDS-Patient and Caregiver inventory
(Cabrini et al., 2009) and the Movement Disorder Society-Unified
PD-Rating Scale (Goetz et al., 2008) were developed lately to
assess the presence of a range of impulsive–compulsive behav-
iors in PD patients, their validity as assessment tools remains
to be further proved (Goetz et al., 2012). The Questionnaire for
Impulsive–Compulsive Disorders in Parkinson’s Disease (QUIP)
was recently developed and validated to detect the presence of
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clinically significant ICDs, DDS, and other compulsive behaviors
(punding, hobbyism, and walkabout) (Weintraub et al., 2009).
The QUIP is consisted of three sections: Section 1 assesses four
ICDs (involving gambling, sexual, buying, and eating behaviors);
Section 2 tests other compulsive behaviors (punding, hobbyism,
and walkabout); and Section 3 checks compulsive medication use
(Weintraub et al., 2009). Recently, QUIP was used to screen the
prevalence of ICBs and subsyndromal ICBs of PD patients in
Malaysia (Lim et al., 2011) and German (Rohde et al., 2013). Papay
et al. (2011) assessed observer variability and validity in report-
ing ICD symptoms using the QUIP. Besides, Tanaka et al. (2013)
developed a Japanese version of QUIP (J-QUIP) and evaluated
the sensitivity, specificity, positive predictive value, and negative
predictive value for each behavior via diagnostic concordance rate
between actual diagnosis and result of J-QUIP in Japanese PD
patients. However, the QUIP is designed to be sensitive but not
highly specific (i.e., it over identifies patients) for ICBs detection,
so a positive result should be followed by a comprehensive clinical
screen to determine the validity and severity of symptoms, as well
as need for clinical management (Weintraub et al., 2009). More-
over, the Questionnaire for Impulsive–Compulsive Disorder in
Parkinson’s Disease-Rating Scale (QUIP-RS), based on the QUIP,
was developed. In contrast to its predecessor, QUIP-RS requires
individuals to rate the severity of each symptom based on its
frequency using a five-point Likert scale. The QUIP-RS detects
subsyndromal behaviors and establishes clear cut-off points with
a good balance between sensitivity and specificity (Weintraub et al.,
2012).
CONCLUSION AND FUTURE PROSPECTION
Though mounting data regarding ICBs have aroused great con-
cerns in recent years, ICBs remain a great challenge in clinical
practice (Figure 1). Vigilance in the prescribing physical symp-
tom is of paramount importance. Exact prevalence rate of ICBs
is still frequently underreported. As PD patients with ICBs have
reduced insights into social consequences of their behaviors, it
turns momentous to screen ICBs using specifically devised and
validated diagnostic tools and to enquire relevant information
from both patients and caregivers. Susceptibilities to ICBs in PD
patients have been associated with specific demographic and clin-
ical characteristics and abnormalities on functional neuroimaging
studies including male gender, higher LEDD, young age at PD
FIGURE 1 |The flowchart of management of ICBs in Parkinson’s disease.
To prevent ICBs occurring, closer follow-up and monitoring are essential.
Once ICBs are diagnosed, the first-choice is adjustment of dose of DAs and
levodopa, but this requires a good balance between ICBs symptoms and
motor disorders. For ICDs, D3 agonists should be reduced; for DDS, the dose
of levodopa is considered to be cut down. With regard to punding, selegiline,
which enhances the levodopa action and has amphetamine-like metabolites,
and bedtime DRT should be withdrawn as well as reducing levodopa dose. In
case motor disorder and psychopathic symptoms occur, levodopa may be
useful for ICDs, and D3 agonists or entacapone may alleviate DDS and
punding as well as antidepressants, antipsychotics, and amantadine.
However, one should be ever vigilant that these could trigger or worsen
concomitant disorders. Antiandrogen cyproterone should be considered for
hypersexuality, especially when there are no other effective drugs. Atypical
neuroleptic drugs could also be used for ICBs, such as olanzapine or
quetiapine, especially for punding patients presenting with psychosis or
reduced sleep time. Besides, cognitive-behavioral therapies have been
evaluated as an efficacious method. Supposing that all interventions
discussed above fail to control symptoms, DBS or DBS plus DRT could also
be considered. Moreover, jejunal levodopa infusion was recently found to be
effective for ICBs, whereas the availability was merely evaluated in small
sample, and thus further larger clinical studies are still needed.
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onset, personal or family history of alcoholism, and impulsive
or novelty-seeking personalities. The pathology of PD, including
the role of different neurotransmitters, likely plays a facilitative
role in developing ICBs but the exact mechanisms remain to be
established. Numerous studies have related ICBs to dopaminer-
gic therapy. Imaging studies also provided additional evidence
to strengthen the link. Given the potentially devastating con-
sequences and lack of effective treatments for ICBs, preventive
strategies do matter. Though ICBs have been considered as side
effects resulting from DRT, levodopa remains the gold standard for
symptomatic treatment in PD patients and should not be withheld
from patients especially in whom sufficient symptomatic control
cannot be otherwise obtained. Whether or not a DA should be
used as early monotherapy largely depends on the perceived risk
of dyskinesias – for which younger age is a major determinant
(Antonini et al., 2009). Readjustment of DRT dose is still the
main way to prevent and control ICBs, but attention should be
drawn to balance ICBs symptoms and motor disorders. More-
over, atypical antipsychotics, antidepressants, amantadine, and
psychosocial interventions can also be prescribed in controlling
episodes of psychosis caused by compulsive DRT use with cau-
tiousness because these drugs may also induce variable degree of
motor function worsening. In addition to the pharmacal therapies
described above, STN-DBS may be another efficacious therapy for
advanced PD patients with the potential not only to allow signif-
icant reductions in drug dose but to improve “off”-medication
motor symptoms (Table S3 in Supplementary Material). Further-
more,Williams et al. (2010) reported that surgery plus best medical
therapy improved patient self-reported quality of life more than
best medical therapy alone in patients with advanced PD. All
in all, the use of emerging, empirically validated treatments for
ICBs should be considered, particularly for patients whose dis-
continuation of DA therapy is not a viable option. Despite many
achievements have been acquired, several unanswered questions
remain. Firstly, what are the main reasons that differentiate PD
patients that develop ICBs from those patients do not develop
ICBs even if they receive the same medication? Although we have
found many risk factors for the development of ICBs, this question
is still unanswered at the level of neuronal function. Furthermore,
why do different PD patients develop differing ICBs presenta-
tions? Individual susceptibilities, disease process, and dopaminer-
gic medications might all contribute to the occurrence of diverse
ICBs, but the accurate nosogenesis should be further investigated.
Finally, what is the relationship between ICDs, DDS, punding, and
substance abuse? Though familiar clinical risk factors and some
common grounds have been observed, the key factors leading
PD patients to substance abuse but not ICDs, DDS, or pund-
ing has not been illustrated. In conclusion, the current goal is
to determine the exact mechanisms in the pathogenesis of ICBs
in PD patients, and then find the corresponding therapy to offer
robust motor benefit without producing ICDs or other serious
side effects.
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